EndometriosisPhase 3ELARIS EM-COCNCT04333576
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
A Phase 3 study testing Elagolix and Combined Oral Contraceptive in people with Endometriosis, run by AbbVie at 179 sites in 2 countries.
Trial summary
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. Read more about this study
- Who is it for?
- Ages 18 to 49 years, women only
- Conditions the study is for
- Endometriosis
- What is being tested?
- Elagolix and Combined Oral Contraceptive
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 800 participants
- Where
- 179 sitesin 2 countries
- Study dates
- 10 Aug 2020to Jul 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 49 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Documented surgical confirmation of endometriosis and associated moderate to severe pain.
- Participants must agree to use dual non-hormonal methods of contraception consistently during washout (if applicable), screening, and 3-month double-blind placebo-controlled treatment periods of the study.
- Participant, in the investigator's opinion must be an appropriate candidate to receive combined oral contraceptives (COCs).
Who cannot join
- Pregnant or breastfeeding or planning a pregnancy until completion of the study.
- Surgical history of hysterectomy or bilateral oophorectomy.
- Participant has osteoporosis or other metabolic bone disease or clinically significant gynecological findings from Screening.
- Participant has any other active chronic pain condition that would interfere with their assessment of endometriosis-related pain.
Trial locations and contacts
179 sites in 2 countries.
179 sites in 2 countries
United States176 sites
Paramount Research Solutions /ID# 218769
Alpharetta, Georgia, 30005
Pinnacle Research Group /ID# 217062
Anniston, Alabama, 36207
Topaz Clinical Research /ID# 218615
Apopka, Florida, 32703-5835
Academia of Women's Health & Endoscopic Surgery /ID# 217260
Atlanta, Georgia, 30328
Gyn & Fertility Specialists /ID# 223015
Atlanta, Georgia, 30342-1731
Atlanta Women's Research Institute /ID# 217303
Atlanta, Georgia, 30342
Rocky Mountain Internal Medicine - Aurora /ID# 245161
Aurora, Colorado, 80012-4505
Ideal Clinical Research Inc. /ID# 218832
Aventura, Florida, 33180
American Health Network of IN, LLC (Avon) /ID# 218023
Avon, Indiana, 46123-7960
Great Lakes Research Group - Bay City /ID# 217099
Bay City, Michigan, 48706
Clinical Inquest Center Ltd /ID# 217961
Beavercreek, Ohio, 45431-2573
ACCEL Research Sites /ID# 218044
Birmingham, Alabama, 35218
Alabama Clinical Therapeutics /ID# 217166
Birmingham, Alabama, 35235-3430
Alabama Clinical Therapeutics /ID# 222301
Birmingham, Alabama, 35235-3430
University of Alabama at Birmingham - Women's and Infant's Center /ID# 224503
Birmingham, Alabama, 35294-7333
Helix Biomedics, LLC /ID# 218649
Boynton Beach, Florida, 33436-6634
Maimonides Medical Center /ID# 248493
Brooklyn, New York, 11219
Investigators Research Group, LLC /ID# 222891
Brownsburg, Indiana, 46112
Invision Health /ID# 218687
Buffalo, New York, 14221-5771
Cooper University Hospital /ID# 227208
Camden, New Jersey, 08103
Neuro-Behavioral Clinical Research, Inc. /ID# 224026
Canton, Ohio, 44720
Duplicate_PMG Research of Charlotte /ID# 217224
Charlotte, North Carolina, 28209
Tyron Medical Partners, PLLC /ID# 245286
Charlotte, North Carolina, 28211-5055
Chattanooga Research and Medicine /ID# 217045
Chattanooga, Tennessee, 37412-3964
Women's Health Care Center Of Chicago /ID# 245164
Chicago, Illinois, 60639-2103
Seven Hills Clinical Research Group /ID# 224941
Cincinnati, Ohio, 45255
Duplicate_Duplicate_University Of Cincinnati Medical Center /ID# 217349
Cincinnati, Ohio, 45267-0585
Olympian Clinical Research /ID# 244426
Clearwater, Florida, 33756
Women's Medical Research Group /ID# 218524
Clearwater, Florida, 33759
MetroHealth Medical Center /ID# 224392
Cleveland, Ohio, 44109
Paramount Research Solutions - College Park /ID# 217358
College Park, Georgia, 30349-3103
Vista Clinical Research /ID# 217151
Columbia, South Carolina, 29201
Duplicate_Columbus Regional Research Ins /ID# 217294
Columbus, Georgia, 31904
Midtown OBGYN North /ID# 222300
Columbus, Georgia, 31909-5715
Central Ohio Clinical Research /ID# 217059
Columbus, Ohio, 43213-3399
Clinical Trials Management - Metairie /ID# 217054
Covington, Louisiana, 70433-4966
Clinical Trials Management, LLC - Covington /ID# 217291
Covington, Louisiana, 70433
DCT - HCWC, LLC dba Discovery Clinical Trials /ID# 217095
Dallas, Texas, 75230
Cedar Health Research /ID# 224407
Dallas, Texas, 75251-2202
Duplicate_The University of Texas Southwestern Medical Center /ID# 217048
Dallas, Texas, 75390-8575
Velocity Clinical Research - Denver /ID# 217297
Denver, Colorado, 80209-3804
Wayne State University, C.S. Mott Center /ID# 248422
Detroit, Michigan, 48201-1406
Doral Medical Research, LLC /ID# 225146
Doral, Florida, 33166-6658
Universal Axon Clinical Research /ID# 248553
Doral, Florida, 33166
Trinity Research Group /ID# 246932
Dothan, Alabama, 36301
Corner Canyon Obstetrics and G /ID# 217289
Draper, Utah, 84020
Carolina Women's Research and Wellness Center /ID# 217133
Durham, North Carolina, 27713
Widewaters Gynecology /ID# 225621
East Syracuse, New York, 13057-3072
Diagnamics Inc. /ID# 225385
Encinitas, California, 92024
HWC Women's Research Center /ID# 246619
Englewood, Ohio, 45322
Horizon Research Group /ID# 217100
Eunice, Louisiana, 70535
Wright State Physicians Health Center /ID# 217272
Fairborn, Ohio, 45324
Southern Women's Specialists PC /ID# 217143
Fairhope, Alabama, 36532-3029
NECCR Fall River LLC /ID# 217108
Fall River, Massachusetts, 02720-2972
Exordia Medical Research, Inc /ID# 217116
Fall River, Massachusetts, 02723
KO Clinical Research, LLC /ID# 217173
Fort Lauderdale, Florida, 33316
Alliance for Multispecialty Research (AMR) - Fort Myers /ID# 217061
Fort Myers, Florida, 33912
Women's Health Advantage /ID# 246580
Fort Wayne, Indiana, 46825
Signature Gyn Services /ID# 217299
Fort Worth, Texas, 76104
Grube Gynecology /ID# 245132
Frackville, Pennsylvania, 17931-2105
SBL Special Services LLC /ID# 224899
Frederick, Maryland, 21702-4301
Progressive Women's Health /ID# 248402
Friendswood, Texas, 77546-3988
Willowbend Health and Wellness - Frisco /ID# 217354
Frisco, Texas, 75035
FMC Science, LLC - OB/GYN - Georgetown /ID# 218654
Georgetown, Texas, 78626-8185
North Valley Women's Care /ID# 217092
Glendale, Arizona, 85308
Boeson Research - Grand Junction /ID# 248580
Grand Junction, Colorado, 81505-1018
Boeson Research - Great Falls /ID# 248560
Great Falls, Montana, 59405-5315
University Medical Group /ID# 217355
Greenville, South Carolina, 29605
Vitalink Research - Greenville /ID# 217075
Greenville, South Carolina, 29615
Advanced Women's Health Institute /ID# 217150
Greenwood Village, Colorado, 80111
Penn State University and Milton S. Hershey Medical Center /ID# 217057
Hershey, Pennsylvania, 17033-2360
UTHealth Women's Research Program - Memorial City /ID# 217362
Houston, Texas, 77024
OBGYN Medical Center Associates - Medical Center Office /ID# 245346
Houston, Texas, 77054-2934
Centex Studies, Inc. - Houston /ID# 217357
Houston, Texas, 77058
Leavitt Womens Healthcare /ID# 217118
Idaho Falls, Idaho, 83404
Womens Healthcare Assoc, DBA /ID# 222153
Idaho Falls, Idaho, 83404
University of Iowa Hospitals and Clinics /ID# 217144
Iowa City, Iowa, 52242
Solutions Through Adv Rch /ID# 220973
Jacksonville, Florida, 32256
Care Partners Clinical Research /ID# 217042
Jacksonville, Florida, 32277
Vida Clinical Research /ID# 245325
Kissimmee, Florida, 34741-2358
Kissimmee Clinical Research /ID# 224749
Kissimmee, Florida, 34741
Atella Clinical Research /ID# 224024
La Palma, California, 90623
Red Rocks OB/GYN /ID# 217103
Lakewood, Colorado, 80228-1810
FMC Science /ID# 217047
Lampasas, Texas, 76550
Private practice: Dr. Rex G. Mabey JR /ID# 217134
Las Vegas, Nevada, 89128
Maximos OB/GYN /ID# 229385
League City, Texas, 77573-2681
Womens Clinic of Lincoln, P.C. /ID# 217136
Lincoln, Nebraska, 68510
Applied Research Center of Arkansas /ID# 248494
Little Rock, Arkansas, 72212-4187
South Florida Wellness & Clinic /ID# 222897
Margate, Florida, 33063
Marion Ob/Gyn Inc. /ID# 244175
Marion, Ohio, 43302-6318
Praetorian Pharmaceutical Research /ID# 217159
Marrero, Louisiana, 70072
Univ Hosp Landerbrook /ID# 217065
Mayfield Heights, Ohio, 44124
Research Memphis Associates, LLC /ID# 218022
Memphis, Tennessee, 38119-3895
Sonora Clinical Research /ID# 222147
Meridian, Idaho, 83646-1144
Southern Clinical Research A /ID# 218028
Metairie, Louisiana, 70001
GRE Clinical Research, LLC /ID# 246579
Miami, Florida, 33145-2457
Gold Coast Health Research, LLC /ID# 248624
Miami, Florida, 33155-1402
Admed Research LLC /ID# 227679
Miami, Florida, 33173
The Miami Research Group Inc /ID# 246578
Miami, Florida, 33174
Innova Pharma Research /ID# 245354
Miami, Florida, 33175-8802
Ocean Blue Medical Research Center, Inc /ID# 217286
Miami Springs, Florida, 33166
Salom Tangir, LLC /ID# 217273
Miramar, Florida, 33027
Boeson Research - Missoula /ID# 248559
Missoula, Montana, 59804-7419
Women's Health Alliance of Mobile /ID# 222591
Mobile, Alabama, 36604-1410
Mobile, OBGYN P.C. /ID# 217135
Mobile, Alabama, 36608
Asr, Llc /Id# 217094
Nampa, Idaho, 83687
Access Clinical Trials, Inc. /ID# 217055
Nashville, Tennessee, 37203
Jersey Shore University Medical Center /ID# 217138
Neptune City, New Jersey, 07753-4859
Eastern Carolina Women's Centr /ID# 222358
New Bern, North Carolina, 28562
Rutgers Robert Wood Johnson /ID# 246933
New Brunswick, New Jersey, 08901
Suncoast Clinical Research Pasco County /ID# 217249
New Port Richey, Florida, 34652
Advanced Research Institute, Inc /ID# 217206
New Port Richey, Florida, 34653
Parkmed NYC /ID# 224333
New York, New York, 10017-4709
Columbia Univ Medical Center /ID# 217113
New York, New York, 10032-3725
New York Presbyterian Hospital Weill Cornell Medical Center /ID# 224329
New York, New York, 10065
Reproductive Assoc of Delaware /ID# 227764
Newark, Delaware, 19713
Health Research of Hampton Roads, Inc. (HRHR) /ID# 217063
Newport News, Virginia, 23606
Clinical Research Partners /ID# 217359
North Chesterfield, Virginia, 23235
Dr. Nader and Associates M.D. P.C. /ID# 223571
North Las Vegas, Nevada, 89030-7187
Segal Institute for Clinical Research /ID# 221518
North Miami, Florida, 33161-5821
Valley Renal Medical Group Research /ID# 228614
Northridge, California, 91324-4622
Futura Research, Org /ID# 217361
Norwalk, California, 90650
Alliance for Multispecialty Research, LLC /ID# 217226
Oak Brook, Illinois, 60523
A Premier Medical Research of FL /ID# 216908
Orange City, Florida, 32763-2833
Osceola Gynecology, LLC - Orlando /ID# 227194
Orlando, Florida, 32806-5412
Omega Research Group /ID# 216907
Orlando, Florida, 32808
Clinical Associates of Orlando /ID# 218114
Orlando, Florida, 32819-8900
Duplicate_Suncoast Clinical Research - Palm Harbor /ID# 219133
Palm Harbor, Florida, 34684
The Advanced Gynecologic Surgery Institute - Park Ridge /ID# 245372
Park Ridge, Illinois, 60068
Advances in Health, Inc. /ID# 217220
Pearland, Texas, 77854
Royal Research,Corp /ID# 221356
Pembroke Pines, Florida, 33027-1003
University of Pennsylvania /ID# 217243
Philadelphia, Pennsylvania, 19104-5502
MomDoc Womens Health Research /ID# 221661
Phoenix, Arizona, 85251
Duplicate_Physicians Research Options /ID# 217302
Pleasant Grove, Utah, 84062
Virginia Women's Health Associates /ID# 227677
Reston, Virginia, 20190-3215
Clinical Trials Virginia, Inc. /ID# 217222
Richmond, Virginia, 23225
Clinical Research Partners LLC - Richmond Forest Ave /ID# 217149
Richmond, Virginia, 23226-3786
Congressional OBGYN /ID# 245349
Rockville, Maryland, 20850-8726
Northern California Research /ID# 217301
Sacramento, California, 95821-2640
Saginaw Valley Med Res Group /ID# 217296
Saginaw, Michigan, 48604
Highland Clinical Research /ID# 224052
Salt Lake City, Utah, 84124
Clinical Trials of Texas, Inc /ID# 217039
San Antonio, Texas, 78229
VIP Trials /ID# 217261
San Antonio, Texas, 78230
Discovery Clinical Trials-San Antonio /ID# 218547
San Antonio, Texas, 78258
A & B Clinical Research /ID# 224471
San Diego, California, 92103-3363
Advanced Clinical Research Center, LLC /ID# 248398
San Diego, California, 92119-3434
Physician Care Clin. Res., LLC /ID# 217264
Sarasota, Florida, 34239
Unity Health- Searcy Medical Center /ID# 217050
Searcy, Arkansas, 72143-4802
Seattle Clinical Research Center /ID# 217117
Seattle, Washington, 98105
GTC Research /ID# 217051
Shawnee Mission, Kansas, 66218
Women's Health Clinic /ID# 217205
Shreveport, Louisiana, 71118-3133
Innovative Women's HealthCare Solutions - Smyrna /ID# 223692
Smyrna, Georgia, 30082-5166
Journey Medical Research Institute - Snellville /ID# 229774
Snellville, Georgia, 30078-6191
North Spokane Women's Health /ID# 217356
Spokane, Washington, 99207
Center for Reproductive Medicine and Robotic Surgery /ID# 223494
St Louis, Missouri, 63141
Richmond OB/GYN Associates PC /ID# 224833
Staten Island, New York, 10306
Duplicate_Palmetto Clinical Research /ID# 217069
Summerville, South Carolina, 29485-7539
Tampa General Hospital - Tampa - General Circle /ID# 217146
Tampa, Florida, 33606
GCP Clinical Research, LLC /ID# 217232
Tampa, Florida, 33609-4044
AC Clinical Research /ID# 227356
Tiffin, Ohio, 44883
Continental Clinical Solutions /ID# 217053
Towson, Maryland, 21204
Tidewater Clinical Research /ID# 217152
Virginia Beach, Virginia, 23456
Medstar Health Research Institute /ID# 244937
Washington D.C., District of Columbia, 20010
James A. Simon, MD, PC /ID# 218116
Washington D.C., District of Columbia, 20036
Center of Reproductive Medicine /ID# 217241
Webster, Texas, 77598
Virtus Research Consultants, LLC /ID# 217052
Wellington, Florida, 33414
Biocentric Healthcare Research /ID# 248582
West Columbia, South Carolina, 29169-3612
The Iowa Clinic, PC /ID# 217351
West Des Moines, Iowa, 50266-8216
Alliance for Multispecialty Research (AMR) - Wichita West /ID# 218040
Wichita, Kansas, 67205-1138
Cypress Medical Research Ctr /ID# 217093
Wichita, Kansas, 67226
Accellacare Wilmington /ID# 217097
Wilmington, North Carolina, 28401
Carolina Medical Trials - Winston-Salem /ID# 223002
Winston-Salem, North Carolina, 27103-4109
Unified Women's Clinical Research /ID# 217132
Winston-Salem, North Carolina, 27103
Unified Women's Clinical Research /ID# 218339
Winston-Salem, North Carolina, 27103
Florida Premier Research Institute, LLC /ID# 224499
Winter Park, Florida, 32789-4681
reading Hospital /ID# 223599
Wyomissing, Pennsylvania, 19611
Puerto Rico3 sites
Advanced Medical Concepts. PSC /ID# 221337
Cidra, 00739
Henry A. Rodriguez Ginorio, MD /ID# 217233
San Juan, 00917-5022
School of Medicine University of Puerto Rico-Medical Science Campus /ID# 217235
San Juan, 00935
About this study
Official title: A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endometriosis and associated pain.
Elagolix is an approved drug for the management of moderate to severe pain associated with endometriosis. Participants are randomly put in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. Adult female participants who still have periods with a diagnosis of endometriosis will be enrolled. Around 800 participants will be enrolled in the study at multiple sites in the United States, including Puerto Rico.
Read more
Participants will receive oral elagolix or placebo tablets in combination with combined oral contraceptive (COC) or placebo capsules for 3 months. All the participants will receive elagolix tablets in combination with COC tablets from Month 4 through Month 18.
There will be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
- Conditions
- Endometriosis
- Being tested
- Elagolix, Placebo, Combined Oral Contraceptive
- Keywords
- Endometriosis, Elagolix, Combined oral contraceptives (COC), Orilissa, Dysmenorrhea
- Medical subject headings
- Endometriosis, Dysmenorrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ElagolixDrug
Also called ABT-620, Orilissa
Tablet:Oral
PlaceboDrug
Tablet:Oral
Combined Oral ContraceptiveDrug
Tablet:Oral
| Study group | Role | What they receive |
|---|---|---|
| Double-Blind: Placebo | Placebo comparator | Participants will receive double-blind placebo on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months. Receives: Drug: Elagolix; Drug: Placebo; Drug: Combined Oral Contraceptive |
| Double-Blind: Elagolix | Experimental | Participants will receive double-blind Elagolix on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months. Receives: Drug: Elagolix; Drug: Combined Oral Contraceptive |
| Double-Blind: Elagolix + COC | Experimental | Participants will receive double-blind elagolix in combination with COC (combined oral contraceptive) on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC for 15 months. Participants will be followed-up for up to 12 months. Receives: Drug: Elagolix; Drug: Combined Oral Contraceptive |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Responders Based on Dysmenorrhea (DYS) Pain Scale
DYS response is measured by the 4-point Endometriosis Daily Pain Impact Scale (none, mild, moderate, severe) and with stable or decreased analgesic use.
Measured: Month 3
Number of Participants Experiencing Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Measured: Up to approximately 50 months
Secondary outcomes (1)
Percentage of Responders Based on Non-Menstrual Pelvic Pain (NMPP) Pain Scale
NMPP response is measured by the 4-point Endometriosis Daily Pain Impact Scale (none, mild, moderate, severe) and with stable or decreased analgesic use.
Measured: Month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2020
- Study start10 Aug 2020
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04333576
- Sponsor's protocol ID
- M18-969
- Acronym
- ELARIS EM-COC
- Status last verified
- Jun 2026
- First submitted
- 2 Apr 2020
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain
- ClinicalTrials.gov ID
- NCT04333576
- Acronym / sponsor ID
- ELARIS EM-COC / M18-969
- Conditions
- Endometriosis
- Keywords
- Endometriosis, Elagolix, Combined oral contraceptives (COC), Orilissa, Dysmenorrhea
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 10 Aug 2020 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 3 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endometriosis and associated pain.
Elagolix is an approved drug for the management of moderate to severe pain associated with endometriosis. Participants are randomly put in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. Adult female participants who still have periods with a diagnosis of endometriosis will be enrolled. Around 800 participants will be enrolled in the study at multiple sites in the United States, including Puerto Rico.
Participants will receive oral elagolix or placebo tablets in combination with combined oral contraceptive (COC) or placebo capsules for 3 months. All the participants will receive elagolix tablets in combination with COC tablets from Month 4 through Month 18.
There will be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Double-Blind: Placebo | Placebo comparator | Drug: Elagolix, Drug: Placebo, Drug: Combined Oral ContraceptiveParticipants will receive double-blind placebo on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months. |
| Double-Blind: Elagolix | Experimental | Drug: Elagolix, Drug: Combined Oral ContraceptiveParticipants will receive double-blind Elagolix on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months. |
| Double-Blind: Elagolix + COC | Experimental | Drug: Elagolix, Drug: Combined Oral ContraceptiveParticipants will receive double-blind elagolix in combination with COC (combined oral contraceptive) on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC for 15 months. Participants will be followed-up for up to 12 months. |
Who may qualify
- Ages
- 18 to 49 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Documented surgical confirmation of endometriosis and associated moderate to severe pain.
- Participants must agree to use dual non-hormonal methods of contraception consistently during washout (if applicable), screening, and 3-month double-blind placebo-controlled treatment periods of the study.
- Participant, in the investigator's opinion must be an appropriate candidate to receive combined oral contraceptives (COCs).
Key exclusion criteria (4 listed)
- Pregnant or breastfeeding or planning a pregnancy until completion of the study.
- Surgical history of hysterectomy or bilateral oophorectomy.
- Participant has osteoporosis or other metabolic bone disease or clinically significant gynecological findings from Screening.
- Participant has any other active chronic pain condition that would interfere with their assessment of endometriosis-related pain.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ElagolixAlso: ABT-620, OrilissaTablet:Oral | Drug | Double-Blind: Elagolix, Double-Blind: Elagolix + COC, Double-Blind: Placebo |
| PlaceboTablet:Oral | Drug | Double-Blind: Placebo |
| Combined Oral ContraceptiveTablet:Oral | Drug | Double-Blind: Elagolix, Double-Blind: Elagolix + COC, Double-Blind: Placebo |
Primary outcome
Percentage of Responders Based on Dysmenorrhea (DYS) Pain Scale
Time frame: Month 3
DYS response is measured by the 4-point Endometriosis Daily Pain Impact Scale (none, mild, moderate, severe) and with stable or decreased analgesic use.
Number of Participants Experiencing Adverse Events (AEs)
Time frame: Up to approximately 50 months
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
1 secondary outcome
Percentage of Responders Based on Non-Menstrual Pelvic Pain (NMPP) Pain Scale
Time frame: Month 3
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
179 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Elagolix and Combined Oral Contraceptive in people with Endometriosis, run by AbbVie at 179 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 179 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Responders Based on Dysmenorrhea (DYS) Pain Scale (time frame: Month 3). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.